Maravai Deferred Long Term Liab from 2010 to 2024
| MRVI Stock | USD 4.96 0.14 2.90% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 2 M | Current Value 2.2 M | Quarterly Volatility 534.6 K |
Check Maravai Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Maravai Lifesciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.8 M, Interest Expense of 33.9 M or Selling General Administrative of 103.3 M, as well as many indicators such as Price To Sales Ratio of 2.84, Dividend Yield of 0.0157 or PTB Ratio of 1.97. Maravai financial statements analysis is a perfect complement when working with Maravai Lifesciences Valuation or Volatility modules.
Maravai | Deferred Long Term Liab |
Latest Maravai Lifesciences' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Maravai Lifesciences Holdings over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Maravai Lifesciences' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Maravai Lifesciences' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Maravai Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 3,099,556 | |
| Geometric Mean | 3,048,722 | |
| Coefficient Of Variation | 17.25 | |
| Mean Deviation | 440,652 | |
| Median | 3,400,000 | |
| Standard Deviation | 534,561 | |
| Sample Variance | 285.8B | |
| Range | 1.4M | |
| R-Value | (0.77) | |
| Mean Square Error | 127.3B | |
| R-Squared | 0.59 | |
| Significance | 0.0009 | |
| Slope | (91,524) | |
| Total Sum of Squares | 4T |
Maravai Deferred Long Term Liab History
About Maravai Lifesciences Financial Statements
Investors use fundamental indicators, such as Maravai Lifesciences' Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Maravai Lifesciences' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 2 M | 2.2 M |
Currently Active Assets on Macroaxis
When determining whether Maravai Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Maravai Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maravai Lifesciences Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maravai Lifesciences Holdings Stock:Check out the analysis of Maravai Lifesciences Correlation against competitors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Earnings Share (1.67) | Revenue Per Share 2.044 | Quarterly Revenue Growth (0.03) | Return On Assets (0.02) |
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.